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Abstract
People with diabetes treated with insulin have often faced blanket bans from safety-
critical occupations, largely because of fear of incapacitation due to hypoglycaemia.
Recent advances in insulin therapies, modes of administration, monitoring, and nonin-
vasive monitoring techniques have allowed stereotypical views to be challenged. The
aviation sector has led the way, in allowing pilots to fly while on insulin. Recently,
countries that have traditionally been opposed to this have changed their minds,
largely due to the increasing evidence of safety. The purpose of this review was to
gather all available information to update clinicans. The physiology and pathophysiol-
ogy underpinning glucose regulation and the management of diabetes in the air all-
owing certain insulin-treated pilots to fly are discussed.
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1 | INTRODUCTION
People with diabetes face daily discrimination and prejudice about the
medical condition with which they live. This prompted the Interna-
tional Diabetes Federation to launch an International Charter of
Rights and Responsibilities of People with Diabetes in 2011.1 The
vision of this charter was to optimize health and quality of life, enable
as normal a life as possible, and reduce and eliminate barriers that
deny realization of full potential as members of society as a whole. A
right was stipulated that people with diabetes should be treated fairly
in employment and career progression whilst acknowledging that
there were certain occupations where identifiable risks may limit their
employment. The overall aim was to reduce the barriers that deny
realization of full potential as members of society but have to be bal-
anced by public safety.1 The risk of hypoglycaemia and incapacitation
is the most widely quoted reason for a blanket ban policy preventing
safety-critical occupations being performed by people with diabetes
managed with insulin.2 Advances including new insulin analogues,
which reduce the risk of hypoglycaemia, insulin pumps, and non-
invasive continuous glucose monitoring (CGM) devices and tech-
niques have led to vastly improved glycaemic control in insulin-
treated diabetes. There has been a reduced frequency of severe hyp-
oglycaemic events and delayed diabetes-related comorbidities. It is
thus possible to reappraise relative risk and extend the boundaries of
what is possible, practical and safe.2 Aviation has been at the fore-
front of these changes. The purpose of this review was to gather all
available information to update clinicians. Methods included searches
using PubMed, together with abstract research for aeromedical scien-
tific meetings. The physiology and pathophysiology underpinning glu-
cose regulation and the management of diabetes in the air, allowing
certain insulin-treated pilots to fly, is discussed.
2 | CERTIFICATION OF PILOTS WITH
DIABETES
There are international and regionally agreed standards for the issue
of the medical certificates which validate a pilot's licence.3 There are
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different classes of certificate corresponding to the types of licence
privilege a pilot wants to exercise. In most countries, a Class 1 medical
certificate is required for a commercial licence, and a Class 2 for a pri-
vate pilot's licence (Class 3 in the United States). In Europe there is
also a light aircraft pilot's licence (LAPL) and medical certificate, with
similar licensing elsewhere for “sports” aircraft.4 The medical stan-
dards are less demanding for Class 2 and again for LAPL, which
reflects the more limited privileges and different levels of risks associ-
ated with these licences.
3 | HISTORY OF CHANGES IN
CERTIFICATION FOR PEOPLE WITH
DIABETES
In 1989, a British Royal Air Force pilot, Douglas Cairns, was diagnosed
with type 1 diabetes. He was immediately discharged from flying
duties. At the time, no country allowed private, commercial or military
flying for pilots with insulin-treated diabetes. He then applied every
year to the UK Civil Aviation Authority to enquire whether there was
any change that might enable people with type 1 diabetes to fly. The
United States in 1996 introduced a policy that allowed people with
well-controlled type 1 diabetes to fly private aircraft, provided there
was the demonstration of good blood glucose control and oversight.
Following the United States's lead, approximately seven other coun-
tries are understood to have at least one private pilot flying with type
1 diabetes.2 The US system for private flying allows pilots to fly any
size of aircraft, single- or multi-engined, without any restrictions. A
similar protocol existed in Israel.2 In 2002, Canada became the first
country to allow insulin-treated people to fly commercial airplanes
and allow Class 1 and Class 2 certificates. This was done on a case-
by-case basis under close supervision and employed a protocol of
twice-hourly blood glucose monitoring.
Taking this opportunity, Douglas Cairns obtained a license from the
Federal Aviation Authority (FAA) in the United States and embarked on
a series of awareness flying projects including the Diabetes World
Flight, which involved an around-the-world trip and also breaking a
15-day record to land in every state in the United States. In 2011, he
flew to the North Pole with the Diabetes Polar Flight, which set a solo
speed record from Alaska to the North Pole. In 2007, several former
and aspiring pilots who had diabetes formed a group titled “Pilots with
Diabetes” with the aim of persuading aviation authorities around the
world to allow pilots to fly commercial aircraft.2
In 2010, the UK Civil Aviation Authority organized an expert
committee to review the scientific knowledge and basis of the blanket
ban and to see whether international policies concerning flying
needed to be amended. It was concluded that a protocol for safe fly-
ing could be developed and this was published on the UK Civil Avia-
tion Authority website.5 At that time, the committee felt that
noninvasive glucose monitoring devices did not provide sufficient
accuracy and a protocol based on finger-prick blood glucose monitor-
ing was developed. In 2012, the United Kingdom began issuing Class
1 medical certificates for commercial flying using the protocol (see
below). Around this time, European Commission regulation came into
force for the issue of Class 1, 2 or LAPL medical certificates in the
European Union. The regulation allowed the application for a deroga-
tion for a joint research programme conducted by two or more mem-
ber states to permit the issue of aeromedical certificates.4 In 2014,
the European Aviation Safety Agency (EASA) approved a joint
research project by the United Kingdom and Ireland to certify insulin-
treated pilots. There was significant resistance and concern from sev-
eral member states and, in 2015, the EASA, an agency of the commis-
sion, clarified interpretation of the regulation such that initial
applicants were no longer able to obtain a Class 1 medical certificate
through the protocol. Only those applicants who already held a com-
mercial licence were able to obtain a Class 1 certificate. In 2016, Aus-
tria joined the protocol which extended the aircraft that could be
flown to any registered in the United Kingdom, Ireland and Austria. In
2019, the FAA announced that they would certificate pilots with
insulin-treated diabetes, including those flying commercially, and pub-
lished a process on their website. This included the use of CGM sys-
tems and remote glucose monitoring (see below).6 In light of this
announcement, other countries are likely to review their existing poli-
cies in the forthcoming months and years.
4 | EFFECTS OF AVIATION AND ALTITUDE
ON THE PHYSIOLOGY AND
PATHOPHYSIOLOGY OF DIABETES
Fasting glucose levels in healthy people exposed acutely or chronically to
very high altitudes have been demonstrated in studies to increase,
decrease or remain unchanged.7–10 It was felt that the difference in
results might be explained by the duration of altitude exposure to which
people were exposed. Most papers suggest that there is an initial
increase in glucose levels with altitude and that with prolonged exposure
there may be a decrease as people acclimatize. The effect of exercise
may also influence the levels, with some reports suggesting increased
blood glucose levels in response to exercise at altitude but not in individ-
uals under resting conditions. Altitude combined with sympathetic activ-
ity during exercise and increased catecholamine levels is thought to be
responsible for these phenomena. Several studies have consistently
shown an increase in plasma and urinary catecholamines in response to
acute altitude exposure.11,12 Others have suggested that the reported
elevation of cortisol during short-term exposure to high altitude could
also contribute to the hyperglycaemia. In contrast, decreased blood glu-
cose levels have been observed after acute exposure to hypobaric hyp-
oxia in people without diabetes whilst in a prolonged fasting state7.
The conventional understanding, therefore, is that hyper-
glycaemia may develop after exposure to high altitudes, probably sec-
ondary to increased stress-related hormones (cortisol and
catecholamines), but hypobaric hypoxia may have an additional effect
of lowering blood glucose levels that becomes more dominant with
prolonged exposure to high altitude.7 In practical terms, commercial
aircraft, although flying at 9 144 metres, are pressurized to simulate
internal atmosphere somewhere between 6000 and 8000 feet, and
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therefore it is unlikely that these changes will have a significant effect
on glucose metabolism during flight. A much greater influence will
be alterations of diet, lack of exercise, and timing of carbohydrate
and food intake in relation to insulin administration. During an
emergency decompression, there may well be a minor effect due
to sudden pressure differences and hypobaric hypoxia but other
factors, such as unintended insulin delivery from insulin pumps via
tubing due to pressure differences and dissolved gasses, may play
a greater role. An innovative study from Australia13 demonstrated
that insulin pumps delivered more insulin than set during decom-
pression associated with flight. It was noted that when commercial
aircraft ascend to 12 192 metres, the cabin pressure decreases by
200 mmHg from 760 mmHg at sea level (international standard
atmosphere) to 560 mmHg, equivalent to a height of 2438 metres.
The Australian group used a model of examining rates of insulin
delivery from pumps placed in a hypobaric chamber where pres-
sures were altered to mimic ascent over 20 minutes and descent
over 20 minutes.13 The pumps on average delivered 0.7 units
excess during ascent and a deficit of 0.5 units during descent.
During a simulated catastrophic decompression from 760 to
260 mm over 1 minute, all pumps delivered insulin of >8 units due
to plunger movement.13 The follow-on study looked at real flights
in a Boeing 767-338 and similar findings were exhibited. In all
studies, the insulin excess or deficit was consistent with the pre-
diction of bubble volume changes due to pressure changes in the
syringe and tubing using Henry's Law.13 With this in mind, the UK
and European Protocol for flying with diabetes stipulates that,
during an emergency decompression, all pilots should ingest car-
bohydrate to counteract the potential excess delivery from insulin
pumps. There is no literature on the effect of pressure changes on
subcutaneous insulin depots. Thus, overall glucose metabolism
may alter subtly with acute changes in pressure; the effects are
small and are likely to be outweighed by changes in eating pat-
terns and lack of exercise during flights. Additional problems due
to acute decompression are important for people on insulin pumps
and corrective action should be taken and clear instructions given
as part of any flying protocol.
5 | DIFFERENT PROTOCOLS USED BY
COUNTRIES TO ALLOW PEOPLE TREATED
WITH INSULIN TO FLY
All protocols have a similar structure, with a detailed clinical assess-
ment looking for hypoglycaemic awareness thresholds, complication
surveillance, and diligence and aptitude in self-managing diabetes.
During flight, blood glucose is measured by a variety of means at
varying time intervals (Table 1). All require monitoring 30 minutes
prior to landing. There are differing acceptable glucose ranges. All
require carbohydrate ingestion if the low threshold is breached
(Table 1).
5.1 | United Kingdom/Ireland/Austria
Pilots with insulin-treated diabetes who apply to join the protocol5
are assessed with essential clinical information including a letter of
support from their diabetes specialist, biochemical and lipid profiles,
diabetes complication surveillance, and a complete ophthalmological
assessment. A detailed history of hypoglycaemia is taken, including
glycaemic thresholds, Gold score for awareness, and detailed assess-
ments of glucose monitoring records.14 Frequency and rate of out-of-
range results are recorded and a flight test is performed with an
instructor/examiner to assess the ability to follow the inflight blood
testing protocol. Pilots test their blood sugar before flight duty
(at least 1 hour before reporting for duty, or at least 2 hours before
flying; this allows satisfactory glycaemic control to be confirmed or
notification of unfitness). Blood glucose determination occurs
30 minutes before take-off, each hour within flight, and 30 minutes
before the anticipated landing time.
A traffic-light system is used, with “green” signifying acceptable
(5.0-15.0 mmol/L), “amber” indicating caution (low 4.0-4.9 mmol/L;
high 15.1-20.0 mmol/L) and “red” requiring immediate action (low
<4.0 mmol/L; high >20.0 mmol/L). Low ‘amber’ values require the
ingestion of 10 to 15 g readily absorbed carbohydrate and re-
measurement after 30 minutes. Low ‘red’ values require the pilot to






















Israel Yes Blood 2-hourly 30 minutes >5.5 mmol/L 3-monthly Yearly No
Canada Yes Blood Every
30 minutes





Yes Blood Hourly 30 minutes 5-15 mmol/L 6-monthly Yearly Yes
New Zealand Yes Blood Hourly 30 minutes >5.5 mmol/L Not
stipulated
Yearly No
United States Yes CGM CGM 4.4-10 mmol/L 3-monthly Yearly No
Abbreviations: CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin.
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hand over duties to the other pilot or, if flying solo, consider landing
as soon as is practical, as well as ingesting 10 to 15 g readily absorbed
carbohydrate. High readings >15.0 mmol/L necessitate a review of
insulin dosing, modification of planned carbohydrate intake, or both. A
high “red” reading also requires duties to be immediately transferred
to the other pilot and, if flying solo, the pilot must consider landing as
soon as is practical.
5.2 | Canada
All subjects apply with the support of their specialist endocrinologist. A
clinical assessment precertification is performed, including complication
surveillance and full ophthalmology assessment. Applicants have to
exhibit good control and self-management with normal hypoglycaemic
thresholds. A meter with a memory chip must be used and, prior to
flight, a blood glucose of 6 to 15 mmol/L must be documented. Glucose
must be measured every 30 minutes during flight. If blood sugar less
than 6 mmol/L is recorded, 10 g of carbohydrate must be ingested.
5.3 | Israel/New Zealand
Military pilots treated with insulin have been reported to be allowed
to fly with a protocol requiring 2-hourly (Israel) and hourly
(New Zealand) blood glucose determinations. The Israeli protocol
requires action if blood sugar falls below 5.5 mmol/L. Pilots are
assessed for clinical signs of complications and hypoglycaemic thresh-
olds. Full medicals including glycated haemoglobin (HbA1c) review
take place annually. The protocols have not been formally published.
5.4 | United States
Initial applicants in the United States need to demonstrate at least
6 months of stability and adequate control using CGM data on a device
that meets FAA requirements. A longer period is required for those
recently diagnosed. Finger-prick data for the previous 90 days is also
required. They must also submit blood tests, including HbA1c, full blood
count, and biochemical and lipid profiles. Eye and cardiac evaluation are
required, including stress electrocardiograms for those over 40 years
old. The applicant must undertake a medical examination with an exam-
iner and all the information is submitted to the FAA for consideration.
Following successful certificate issue, there is frequent follow-up
with the submission of 3 monthly endocrinology and blood test
reports that are collected and submitted to the FAA every 6 months,
along with notification of flying activity, CGM data, and a record of
any in-flight actions required to maintain blood glucose levels within
an acceptable range. Regular eye and cardiology reviews are also
required. Pilots may use insulin pumps as long as they have the ability
to suspend insulin for predictive low glucose or predicted pressure
changes. Both pumps and CGM devices must be US Food and Drug
Administration-approved and compatible with each other.
5.5 | Comparison of aviation with other modes of
transport
There are over 18 million people with diabetes in the United States
and a large proportion drive motor vehicles. Driving is not a right but
greatly facilitates work, family and social interactions and access to
facilities/services. The volume of road transport driving has led to
advances in transport regulation concerning the medical fitness of a
person with diabetes to drive and the means of assessing and regulat-
ing such driving.
The European Commission directives on driving, particularly one
in 2006, led to the current evolution of European statutory regula-
tions for driving by people with diabetes in all European States,
including the United Kingdom. This evolution has led to better-
defined criteria for Group 1 vehicle licences and broadening of access
to driving for Group 2 licence holders.15
The focus on hypoglycaemia as the principal safety factor in driv-
ing has led to a logical divide between the processes used for drivers
treated with insulin, insulin secretagogues or other medicines known
to produce hypoglycaemia as compared to drivers treated solely with
medicines that do not produce hypoglycaemia and are unlikely to
impair driving performance.15–17
Drivers treated with insulin, insulin secretagogues, or other medi-
cines known to produce hypoglycaemia are required to demonstrate a
safe or acceptable level of hypoglycaemia awareness, with a move
away from unrealistic or ill-defined criteria such as full awareness of
hypoglycaemia. The concept of severe hypoglycaemia has been
defined as requiring the assistance of others, and parameters have
been defined to allow Group 1 driving in closely regulated situations
once this has occurred.15–17 Drivers treated with insulin, insulin secre-
tagogues, or other medicines known to produce hypoglycaemia are
required to demonstrate adequate glucose testing at times relevant to
driving. The dataset required of Group 2 drivers is considerably more
detailed.15–17
Drivers treated solely with medicines that do not produce
hypoglycaemia and are therefore unlikely to impair driving perfor-
mance have experienced more open regulation and, in some circum-
stances, may not need to inform regulatory bodies for Group 1 or
Group 2 licensing.16
Diabetes complications causing visual impairment or peripheral
sensory loss have evolved to be dealt with separately under the
assessment processes for driving.16,17 The evolution has been swift,
has demonstrated safety, and has been accepted by both drivers with
diabetes and by other road users/society.
6 | PUBLISHED DATA OF PEOPLE
TREATED WITH INSULIN WHO ARE
ALLOWED TO FLY
Although several countries allow pilots to fly for leisure, no data have
been published to evaluate the safety and the performance of any of
their protocols. A study from Israel described the use of a different
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protocol of self-monitoring by five military aviators, who measured
blood glucose half an hour before take-off and every 2 hours on long
flights, but any out-of-range levels were not reported, nor was
whether any remedial action was required.18 Similarly, results from
insulin-treated pilots certified to fly commercially in Canada have
been reported as personal abstracts at aero-medical meetings but, to
our knowledge, no formal evaluation of blood glucose levels or rate of
out-of-range values have been published.19
The first peer-reviewed paper reporting data from insulin-treated
commercial pilots came from the United Kingdom.20 This reported
9000 flying hours from 16 Class 1 pilots. There were no reported
safety issues and the protocol was found to be feasible and practical.
The medical records for all Class 1 pilots with insulin-treated diabetes
certificated by the UK Civil Aviation Authority were reviewed. Demo-
graphic information, diabetes history and management data were col-
lated. All available HbA1c values pre- and postcertification were
obtained, together with all in-flight blood glucose monitoring values.
Class 1 medical certificates had been issued to 26 pilots with
insulin-treated diabetes between 2012 and 2015. All were male, with
a median age of 41 years, 22 (84.6%) had type 1 diabetes, with a
median (range) duration of diabetes of 7.75 (1-19) years.
Before and after certification HbA1c was unchanged (53.1 mmol/
mol [95% CI 49.7-56.5 ] vs 54.8 mmol/mol [95% CI 50.9-58.8 ]), with
a mean follow-up of 19.5 months. This result unequivocally showed
that pilots did not run with higher blood glucose levels and overall dia-
betes control did not deteriorate with the attainment of a Class 1 med-
ical certificate. The blood glucose measurement protocol was
demonstrated to be both practical and feasible. Pilots had cumulative
recordings of 8897 pre- and in-flight blood glucose values for
4900 hours of flying. Only 186 readings were out of range: 181 were
in the “caution” amber range (4.0-5.0 mmol/L or 15.0-20.0 mmol/L),
with five in the “immediate action” red range (<4.0 or >20.0 mmol/L).
Appropriate action and retesting were undertaken and no adverse
safety events were reported.
A much more extensive follow-on study, reporting over 22 000
flying hours with 49 pilots from the United Kingdom, Ireland and Aus-
tria (partners in the EASA ARA.MED.330 protocol) has recently been
reported, and represents the largest amount of systematically col-
lected data from insulin-treated people undergoing a safety-critical
occupation.21
A total of 49 pilots issued Class 1 or Class 2 medical certificates
for type 1 (84%) or type 2 (16%) diabetes were studied. The median
diabetes duration was 10.9 years. The mean precertification HbA1c
was 55.0 mmol/mol (7.2%) and the postcertification mean was
55.1 mmol/mol (7.2%; P = 0.97). A total of 38 621 blood glucose
values were recorded during 22 078 flying hours. Overall, 97.69% of
measurements were within the “green” range, 1.42% of values were
within the low “amber” range, 0.75% were within the high ‘amber’
range, 0.12% were within the low “red” range and 0.02% were within
the high ‘red’ range. An interesting observation was that out-of-range
readings decreased from 5.7% in 2013 to 1.2% in 2019. This may be
attributable to the widespread introduction of noninvasive CGM sys-
tems which most pilots use in parallel to the finger-prick glucose
monitoring protocol. No safety concerns have emerged using this
established protocol, which has allowed pilots with insulin-treated dia-
betes to safely undertake complex safety-critical occupational duties.
7 | IMPLICATIONS FOR EMPLOYMENT
SECTORS OTHER THAN AVIATION
The high-value, closely controlled, and regulated environment of avia-
tion has facilitated data collection in controlled situations, which now
becomes applicable to wider uses including driving, occupational
health, and relative risk assessment.21 The large volumes of detailed
data produced by pilots provide a protocol and basis for the safe func-
tioning of individuals treated with hypoglycaemic agents. These proto-
cols and data now allow the empowerment of individuals with
diabetes and the return of a valuable sector of society to some pro-
ductive activities.
8 | NEW TECHNOLOGIES AND THE
FUTURE
Advances in insulin analogue design leading to more predictable and
physiological insulin pharmacokinetic and pharmacodynamics profiles
has helped considerably in enabling flying protocols to work. Insulin
delivery systems are also advancing and recent advances in digital
technology may also help to tailor insulin to physiological need.
Although there have been major advances in closed-loop systems and
the algorithms that govern them, the different insulin delivery at alti-
tude discussed earlier, although minor, will have to be evaluated for-
mally before such systems can be certified in the future.
Noninvasive glucose monitoring techniques are being widely
introduced and have led to an increase in the time in range and also
reduce the number of episodes of, severity of and time spent in hypo-
and hyperglycaemia.22,23 This technology has been suggested as appli-
cable for use in the cockpit of aircraft.22,23 Many of the pilots flying as
a result of the EASA ARA.MED.330 protocol use CGM devices in
addition to the protocol-stipulated testing of finger-prick blood sam-
ples during duty periods. It is of considerable interest that the number
of out-of-range glucose levels while flying has declined considerably
since the widespread introduction and availability of noninvasive
CGM systems. Further research on the use of real-time CGM during
flying is needed and a formal evaluation of CGM is being undertaken
in parallel with the EASA ARA.MED.330 protocol and should report in
2021 (NCT04225455).
This new technology and recent consensus guidance concerning
desirable glucose ranges, including new definitions of hypoglycaemia,
could lead to modifications of the current protocols which are based
on glucose monitoring using finger prick and meters.24 Once the
safety of this technology has been proven, it could play a fundamental
role in persuading aviation and driving regulatory authorities world-
wide to adopt more flexible licensing policies for pilots and drivers
with insulin-treated diabetes mellitus. The US FAA has recently
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announced that the United States, like Canada, the United Kingdom,
Ireland and Austria, will allow pilots with insulin-treated diabetes to
fly commercial aircraft. Allowing CGM in the US protocol represents a
major step forward in this debate.6
9 | CONCLUSION
Until relatively recently it was considered an unacceptable risk to allow
insulin-treated pilots to fly aircraft. With the advent of new monitoring
systems, modern insulin analogues and insulin delivery systems it has
been shown that the risks are now acceptable. In parallel with the
improvement in clinical care has been a reevaluation of societies' discrimi-
nation laws that also has enabled progress. Many countries are now on
the cusp of following Canada, the United Kingdom, Ireland, Austria and,
more recently, the United States in certificating insulin-treated pilots.
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